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Identity 
Location : 11q22.3-q23.1 
DNA/RNA 
Description 
66 exons spanning 184 kb of genomic DNA; numerous 
Alu and Lime sequences. 
Transcription 
Alternative exons 1a and 1b; initiation codon lies 
within exon 4; 12 kb transcript with a 9.2 kb of coding 
sequence.  
The ATM promotor is bi-directional and also directs 
the transcription of the E14/NPAT/CAND3 gene. 
Protein 
Description 
3056 amino acids; 350 kDa; contains a Pl 3-kinase-like 
domain (phosphatidylinositol 3-prime kinase). 
Expression 
Found in all tissues. 
Localisation 
Mostly in the nucleus throughout all stages of the cell 
cycle. 
Function 
Initiates cell cycle checkpoints in response to double-
strand DNA breaks by phosphorylating p53, cAbl, IkB-
alpha and chk1, as well as other targets; in certain types 
of tissues ATM inhibits radiation-induced, p53- 
dependent apoptosis; a possible role in intercellular 
signaling has also been suggested. 
Homology 
Phosphatidylinositol 3-kinase (PI3K)-like proteins, 




Various types of mutations have been described, 
dispersed throughout the gene, and therefore most 
patients are compound heterozygotes; most mutations 
appear to inactivate the ATM protein by truncation, 
large deletions, or annulation of initiation or 
termination, although missense mutations have been 
described in the PI3 kinase domain and the leucine 
zipper motif. 
Somatic 





Ataxia telangiectasia is a progressive cerebellar 
degenerative disease with telangiectasia, 
immunodeficiency, cancer risk, radiosensitivity, and 
chromosomal instability. 
Prognosis 
Poor: median age at death: 17 years; survival rarely 
exceeds 30 years, though survival is increasing with 
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Spontaneous chromatid/chromosome breaks; non 
clonal stable chromosome rearrangements involving 
immunoglobulin superfamilly genes e.g. 
inv(7)(p14q35); clonal rearrangements. 
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